vimarsana.com

Page 23 - தேசிய மருந்துகள் ஒழுங்குமுறை அதிகாரம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

LankaWeb – India welcomes emergency use approval of COVISHIELD vaccines in Sri Lanka

Posted on January 22nd, 2021 Courtesy Adaderana The Government of Sri Lanka has conveyed that approval was granted for the emergency use of COVISHIELD vaccines, says the Indian High Commission in Sri Lanka. In a tweet posted today (January 22), the High Commission said this clears the way to schedule the delivery of vaccines from India to the island nation. Welcome emergency use approval of COVISHIELD vaccines by Government of Sri Lanka. This clears the way for scheduling delivery of the vaccine from #India to #lka. #VaccineMaitri #AffordableVaccine4All” COVISHIELD is the local name for the Oxford-AstraZeneca vaccine developed in the United Kingdom.

India to send gift of COVID vaccines to Sri Lanka next week

India to send gift of COVID vaccines to Sri Lanka next week The island nation will get 500,000 doses of the Made in India Covishield vaccine on January 27. Share Updated: Jan 23, 2021, 05:55 PM IST India will be sending a gift of COVID vaccines to Sri Lanka next week. Sri Lankan President Gotabaya Rajapaksa has announced, the vaccine will reach the country on January 27. The island nation will get 500,000 doses of the Made in India Covishield vaccine and it will become the eighth country to which India is gifting COVID vaccines since it began its country-wide mega immunisation programme on January 16. Starting Wednesday, India has gifted vaccines to seven countries in the region as part of its neighbourhood-first policy Bhutan (150,000), Maldives (100,000), Nepal (One million), Bangladesh (2 million), Myanmar (1.5 M), Seychelles (50,000) and Mauritius (100,000).

The truth behind the rumours on Facia

Tharanga Lanka Weerawardana Alaris Lanka Pvt Ltd conducted a press conference recently to explain to the media regarding the false rumours about their brand “Facia Premium”. Mr. Tharanga Lanka Weerawardana, Chairman and the Managing Director of Alaris Group of Companies stated that a false letter baring the letterhead of the National Medicine Regulatory Authority and forged signature of Dr. Kamal Jayasinghe who is the CEO of the National Medicines Regulatory Authority stating that the product Facia Premium has been banned has been circulated in some print and social media. The CEO of NMRA has denied the issuance of such letter and instructed the Director of the Fraud Investigation Bureau to conduct an investigation on priority basis.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.